What sets treatment by Dr. Baum and his team at Bad Berka apart from PRLT offered at other medical centers in Europe is not only a individualized approach to dosimetry and treatment, but also the view that patients should be administered with lower amounts of radioactivity at more frequent and prolonged intervals (3-6 months in between therapies), rather than given a high dose of radiation at shorter intervals.  Dr. Baum and his team have published results of their approach as applied to patients from 2013 through 2016 in the Journal of Nuclear Medicine in 2016.

The individualized approach is made largely possible by the use of the 68-Gallium-PSMA PET/CT scan. The 68-Ga PET/CT scan is used to calculate the Standard Uptake Values

To achieve the diagnosis and treatment of metastatic castration-resistant prostate cancer (mCRPC) patients under one roof, the team consists of: the Department of Nuclear Medicine / PET Center (Head: Prof. Dr. RP Baum), the Department of Internal Medicine, Gastroenterology and Endocrinology (Head: Prof. Dr. D . Hörsch), the Department of General Surgery / Abdominal Surgery (Head: PD Dr. M. Hommann), the Center for Diagnostic and Interventional Radiology (Head: Dr. J. Leonardi and Dr. A. Petrovitch).  All departments work together as a team on metastatic castration-resistant prostate cancer (mCRPC).

The Centre supports interdisciplinary pain management (led by Dr. J. Lutz) and the Department of Palliative Medicine (Director: Dr